Central Nervous System Pharmacology Practice Questions

Q: A drug 'X' is more selective for the $\alpha_1$ subtype of GABA-A receptors. It has hypnotic action but absent or little antianxiety, muscle relaxant, and anticonvulsant actions. Which of the following can be 'X'?

Zolpidem. **Explanation:** The GABA-A receptor is a pentameric chloride channel. Benzodiazepines (BZDs) are non-selective and bind to various subtypes ($\alpha_1, \alpha_2, \alpha_3, \alpha_5$). However, the **"Z-drugs"** (Zolpidem, Zaleplon) are characterized by their **selective binding to the $\alpha_1$ subunit** (BZ1 receptor). * **$\alpha_1$ subunit:** Mediates sedation, hypnosis, and amnesia. * **$\alpha_2$ and $\alpha_3$ subunits:** Mediate anxiolytic and muscle relaxant properties. * **$\alpha_5$ subunit:** Associated with cognitive impairment. Since **Zolpidem** is highly selective for the $\alpha_1$ subunit, it provides potent hypnotic effects with minimal impact on anxiety, muscle tone, or seizure threshold. This makes it ideal for treating insomnia without the "hangover" effects or motor impairment associated with traditional BZDs. **Analysis of Incorrect Options:** * **A. Zopiclone:** While also a "Z-drug," it is **less selective** for the $\alpha_1$ subunit compared to Zolpidem and Zaleplon, often exhibiting some residual BZD-like effects. * **C. Flumazenil:** This is a competitive **GABA-A receptor antagonist**. It reverses the effects of BZDs and Z-drugs but does not possess hypnotic properties itself. * **D. Melatonin:** This is a hormone that regulates the circadian rhythm by acting on **MT1 and MT2 receptors** in the suprachiasmatic nucleus, not the GABA-A receptor. **High-Yield Clinical Pearls for NEET-PG:** * **Zolpidem** has a short half-life (~2 hours) and is preferred for sleep induction. * **Zaleplon** has the shortest half-life and is useful for delayed sleep onset. * **Eszopiclone** has the longest half-life among Z-drugs and is used for sleep maintenance. * Unlike BZDs, Z-drugs cause **minimal disruption of sleep architecture** (NREM/REM stages).

Q: All of the following can result in serotonin syndrome when combined with MAO inhibitors, except?

Tyramine containing foods. The core of this question lies in distinguishing between **Serotonin Syndrome** and the **Cheese Reaction (Hypertensive Crisis)**.1. Why Tyramine containing foods is the correct answer:When MAO inhibitors (especially non-selective ones) are combined with tyramine-rich foods (e.g., aged cheese, red wine), it results in the **"Cheese Reaction."** Tyramine acts as an indirect sympathomimetic, displacing stored norepinephrine from nerve endings. Since MAO is inhibited, norepinephrine is not degraded, leading to massive sympathetic overactivity and a **hypertensive crisis**, not serotonin syndrome [1].2. Why the other options are incorrect:* **SSRIs (Option B):** These are the most common triggers for Serotonin Syndrome when combined with MAOIs. They prevent the reuptake of serotonin, while MAOIs prevent its breakdown, leading to toxic levels of synaptic serotonin [2].* **TCAs (Option A):** Most TCAs (especially Clomipramine) inhibit serotonin reuptake. Combining them with MAOIs significantly increases the risk of serotonin syndrome.* **Carbamazepine (Option C):** Although primarily an anticonvulsant, Carbamazepine has a tricyclic structure and weak serotonin reuptake inhibitory properties. It is clinically contraindicated with MAOIs due to the risk of serotonin toxicity.Clinical Pearls for NEET-PG:* **Serotonin Syndrome Triad:** Cognitive effects (confusion, hypomania), Autonomic hyperactivity (diaphoresis, tachycardia), and Somatic effects (hyperreflexia, **clonus**, tremor).* **Management:** The specific antidote for Serotonin Syndrome is **Cyproheptadine** (5-HT2A antagonist).* **Washout Period:** Always maintain a 14-day gap when switching between MAOIs and other antidepressants (5 weeks for Fluoxetine due to its long half-life).

Q: Nimodipine is used in the management of which condition?

Subarachnoid hemorrhage. **Explanation:** **Nimodipine** is a second-generation dihydropyridine calcium channel blocker (CCB). While most CCBs are used for hypertension, Nimodipine is unique due to its **high lipid solubility**, which allows it to readily cross the blood-brain barrier and exert a selective effect on cerebral arteries. **Why Subarachnoid Hemorrhage (SAH) is correct:** The primary cause of morbidity and mortality following a subarachnoid hemorrhage (usually from a ruptured aneurysm) is **delayed cerebral ischemia** caused by **vasospasm**. Vasospasm typically occurs 4–14 days after the initial bleed. Nimodipine prevents and reverses this vasospasm by inhibiting calcium influx into the smooth muscle cells of cerebral vessels, thereby improving neurological outcomes and reducing the incidence of ischemic deficits. **Why other options are incorrect:** * **Subdural, Extradural, and Intraventricular Hemorrhages:** These conditions are primarily structural/surgical emergencies (often traumatic). While they involve intracranial bleeding, they are not typically associated with the specific, delayed, chemically-mediated arterial vasospasm seen in SAH. Therefore, Nimodipine provides no therapeutic benefit in these scenarios. **High-Yield Clinical Pearls for NEET-PG:** * **Route & Timing:** It should be started within 96 hours of SAH onset and continued for 21 days. * **Drug Class:** Dihydropyridine CCB (selective for cerebral vasculature). * **Primary Goal:** It does not "stop" the bleed; it prevents **secondary ischemia** due to vasospasm. * **Side Effect:** Hypotension is the most common adverse effect to monitor.

Q: Which of the following agents does not bind to GABA receptor chloride channels?

Buspirone. ### Explanation The **GABA-A receptor** is a ligand-gated chloride channel. Several classes of drugs act as positive allosteric modulators by binding to specific sites on this receptor complex to increase chloride conductance, leading to hyperpolarization and CNS depression. **Why Buspirone is the Correct Answer:** **Buspirone** is a non-benzodiazepine anxiolytic that does **not** act on the GABA system. Its mechanism of action involves acting as a **selective partial agonist at the 5-HT1A (Serotonin) receptor**. It lacks sedative, hypnotic, anticonvulsant, and muscle relaxant properties, making it unique among anxiolytics. **Analysis of Incorrect Options:** * **Ethanol (A):** Alcohol facilitates GABA-A receptor-mediated chloride currents by binding to a specific transmembrane site, contributing to its sedative-hypnotic effects. * **Alphaxolone (B):** This is a synthetic neurosteroid used in anesthesia. Neurosteroids bind to a distinct site on the GABA-A receptor (different from the benzodiazepine site) to enhance chloride channel opening. * **Zolpidem (C):** A "Z-drug" (non-benzodiazepine sedative), it binds selectively to the **α1 subunit** of the GABA-A receptor (BZ1 site). **High-Yield Clinical Pearls for NEET-PG:** 1. **Buspirone Lag Time:** Unlike benzodiazepines, Buspirone takes **2–4 weeks** to show therapeutic effects; it is used for Generalized Anxiety Disorder (GAD) but not for acute anxiety or panic attacks. 2. **No Abuse Potential:** Buspirone does not cause physical dependence or withdrawal symptoms and does not potentiate the effects of alcohol. 3. **GABA-A vs. GABA-B:** Remember that GABA-A is ionotropic (Chloride channel), while GABA-B is metabotropic (G-protein coupled, linked to Potassium channels). **Baclofen** is the prototype GABA-B agonist.

Q: A person taking tricyclic antidepressants presents with blurred vision and dry mouth. These adverse effects result from the blockade of which receptors?

M3 muscarinic receptors. **Explanation:** Tricyclic Antidepressants (TCAs), such as Amitriptyline and Imipramine, are known for their "dirty drug" profile, meaning they interact with multiple receptor systems beyond serotonin and norepinephrine reuptake inhibition. **1. Why M3 Muscarinic Blockade is Correct:** TCAs possess potent **anticholinergic (antimuscarinic)** properties. The M3 muscarinic receptors are primarily responsible for parasympathetic functions such as salivation and ocular accommodation. * **Dry Mouth (Xerostomia):** Results from the blockade of M3 receptors on salivary glands. * **Blurred Vision:** Results from the blockade of M3 receptors on the ciliary muscle (causing cycloplegia/loss of accommodation) and the sphincter pupillae (causing mydriasis). **2. Analysis of Incorrect Options:** * **B. GABA receptors:** TCAs do not block GABA receptors; however, at high doses, they can inhibit GABAergic transmission, which lowers the seizure threshold—a common feature of TCA overdose. * **C. H1 Histamine receptors:** Blockade of H1 receptors by TCAs leads to **sedation** and **weight gain**, not the atropine-like symptoms described. * **D. 5HT2 receptors:** While some TCAs may antagonize serotonin receptors, this action is generally associated with antidepressant efficacy or metabolic side effects, not dry mouth or blurred vision. **Clinical Pearls for NEET-PG:** * **The "3 C’s" of TCA Toxicity:** **C**oma, **C**onvulsions, and **C**ardiotoxicity (due to Na+ channel blockade leading to QRS widening). * **Alpha-1 Blockade:** TCAs also block $\alpha_1$ receptors, leading to **orthostatic hypotension**. * **Contraindication:** Due to their anticholinergic effects, TCAs should be avoided in patients with **Glaucoma** (can precipitate acute angle-closure) and **Benign Prostatic Hyperplasia (BPH)** (can cause urinary retention).

Q: What drug is given for a metoclopramide-induced dystonic reaction?

Promethazine. **Explanation:** **Mechanism of Action:** Metoclopramide is a potent **D2 receptor antagonist**. By blocking dopamine in the nigrostriatal pathway, it creates a chemical imbalance where cholinergic (acetylcholine) activity becomes relatively overactive. This results in **Extrapyramidal Side Effects (EPS)**, most commonly **acute dystonia** (e.g., torticollis, facial grimacing, or oculogyric crisis). To treat this, a drug with strong **central anticholinergic properties** is required to restore the dopamine-acetylcholine balance. **Why Promethazine is Correct:** **Promethazine** is a first-generation antihistamine that possesses potent **antimuscarinic (anticholinergic)** activity. It effectively crosses the blood-brain barrier to antagonize the excess cholinergic activity, providing rapid relief from dystonic spasms. **Analysis of Incorrect Options:** * **Pheniramine:** While it is an antihistamine, its central anticholinergic potency is significantly lower than promethazine or diphenhydramine, making it less effective for acute EPS. * **Chlorpropamide:** This is a first-generation sulfonylurea used in Diabetes Mellitus; it has no role in treating movement disorders. * **Prochlorperazine:** This is a dopamine antagonist (antipsychotic/antiemetic) itself. Giving it would **worsen** the dystonia by further blocking D2 receptors. **NEET-PG High-Yield Pearls:** 1. **Drug of Choice (DOC):** For drug-induced acute dystonia, the parenteral DOC is usually **Benztropine** or **Diphenhydramine**. In the Indian context, **Promethazine** is frequently used and tested. 2. **Akathisia:** The most common EPS of metoclopramide; managed by Propropanol. 3. **Tardive Dyskinesia:** A late-onset EPS; managed by Valbenazine or Deutetrabenazine (VMAT2 inhibitors). 4. **Avoid in Children:** Metoclopramide is prone to causing dystonia in children and young adults; use with caution.

Q: Which NMDA antagonist is used in the treatment of Alzheimer's disease?

Memantine. **Explanation:** **Correct Answer: A. Memantine** Alzheimer’s disease is associated with overstimulation of NMDA (N-methyl-D-aspartate) receptors by glutamate, leading to excessive calcium influx and neuronal excitability (excitotoxicity). **Memantine** is a non-competitive, low-affinity **NMDA receptor antagonist**. It blocks the receptor only when it is pathologically overactivated, thereby preventing neurotoxicity while allowing normal physiological signaling required for memory. It is specifically indicated for **moderate-to-severe** Alzheimer’s disease. **Incorrect Options:** * **B, C, and D (Rivastigmine, Donepezil, Galantamine):** These drugs are **Acetylcholinesterase (AChE) inhibitors**. They work by increasing the concentration of acetylcholine in the synaptic cleft. Unlike Memantine, they are primarily used for **mild-to-moderate** Alzheimer’s disease. * *Rivastigmine* is unique as it inhibits both AChE and Butyrylcholinesterase (BChE) and is available as a transdermal patch. * *Galantamine* also acts as a nicotinic receptor modulator. **High-Yield Clinical Pearls for NEET-PG:** * **Combination Therapy:** Memantine is often added to Donepezil in patients with progressing dementia (synergistic effect). * **Side Effects:** Memantine is generally well-tolerated but can cause dizziness, headache, and constipation. * **NMDA Antagonists in CNS:** Other important NMDA antagonists include **Ketamine** (anesthetic), **Amantadine** (anti-Parkinsonian), and **Dextromethorphan** (antitussive). * **Drug of Choice:** Donepezil is the most commonly used first-line agent for Alzheimer’s due to its once-daily dosing.

Q: Which of the following is the calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA for the treatment of acute migraine attacks?

Rimegepant. **Explanation:** **Rimegepant** belongs to a class of drugs known as **Gepants**, which are small-molecule **CGRP receptor antagonists**. CGRP is a potent neuropeptide involved in pain transmission and vasodilation during migraine pathophysiology. Unlike older therapies, Gepants block the CGRP receptor directly without causing vasoconstriction, making them safer for patients with cardiovascular risks. Rimegepant is unique as it is FDA-approved for both the **acute treatment** and the **preventive treatment** of migraine. **Analysis of Incorrect Options:** * **Lasmiditan (Option B):** This is a selective **5-HT1F receptor agonist**. While used for acute migraine, it works by inhibiting trigeminal nerve firing without vasoconstriction, but it does not target the CGRP receptor. * **Eletriptan (Option C):** A standard **Triptan** (5-HT1B/1D agonist). It causes cranial vasoconstriction and is contraindicated in patients with ischemic heart disease. * **Erenumab (Option D):** While this targets the CGRP pathway, it is a **monoclonal antibody** (mAb) directed against the CGRP receptor. It is administered parenterally and is used exclusively for **prophylaxis**, not acute attacks. **High-Yield NEET-PG Pearls:** * **Gepants (Rimegepant, Ubrogepant):** Oral CGRP antagonists for acute migraine; no vasoconstriction (safe in CAD). * **CGRP Monoclonal Antibodies:** Erenumab (targets receptor); Fremanezumab, Galcanezumab, and Eptinezumab (target the CGRP ligand). All are for **prophylaxis**. * **Drug of Choice (DOC):** Sumatriptan remains the DOC for acute severe migraine, while Propranolol is the DOC for prophylaxis.

Q: Which drug has proven efficacy in bipolar depression?

Lamotrigine. **Explanation:** The management of Bipolar Disorder is divided into two phases: treating acute episodes (mania or depression) and maintenance therapy. While many anticonvulsants act as mood stabilizers, their efficacy profiles differ significantly. **Why Lamotrigine is Correct:** **Lamotrigine** is unique among anticonvulsants because its primary strength lies in the **prevention and treatment of the depressive phase** of bipolar disorder. It acts by inhibiting voltage-gated sodium channels and modulating the release of glutamate. It is FDA-approved for the maintenance treatment of Bipolar I disorder to delay the time to occurrence of mood episodes, specifically depression. **Analysis of Incorrect Options:** * **Carbamazepine:** Primarily used for acute mania and prophylaxis. It is less effective for the depressive phase and is often considered a second-line agent due to its enzyme-inducing properties and side-effect profile. * **Valproate:** This is a first-line drug for **acute mania** and mixed episodes. While it is an excellent mood stabilizer for preventing future manic episodes, it has limited proven efficacy in treating acute bipolar depression. * **Tiagabine:** An anticonvulsant that works by inhibiting GABA reuptake (GAT-1 inhibitor). It has no established role or proven efficacy in the treatment of bipolar disorder. **High-Yield Clinical Pearls for NEET-PG:** * **The "Rash" Warning:** The most serious side effect of Lamotrigine is **Stevens-Johnson Syndrome (SJS)** or Toxic Epidermal Necrolysis. To minimize this risk, the drug must be started at a very low dose and titrated slowly ("Start low, go slow"). * **Drug Interaction:** Valproate inhibits the metabolism of Lamotrigine, significantly increasing its plasma levels and the risk of SJS. * **Other drugs for Bipolar Depression:** Apart from Lamotrigine, other first-line options include **Quetiapine**, **Lurasidone**, and the **Olanzapine-Fluoxetine combination (OFC)**.

Q: What is the antidote for methyl alcohol poisoning?

Fomepizole. **Explanation:** Methyl alcohol (methanol) poisoning is a medical emergency characterized by metabolic acidosis and retinal damage. The toxicity is not caused by methanol itself, but by its metabolites: **Formaldehyde** and **Formic acid**, produced via the enzyme **Alcohol Dehydrogenase (ADH)**. **Why Fomepizole is the Correct Answer:** Fomepizole is a potent **competitive inhibitor of Alcohol Dehydrogenase**. By blocking this enzyme, it prevents the conversion of methanol into its toxic metabolites. This allows the parent methanol to be excreted harmlessly by the kidneys or removed via hemodialysis. It is preferred over the traditional antidote, Ethanol, because it does not cause CNS depression or hypoglycemia and has a predictable pharmacokinetic profile. **Analysis of Incorrect Options:** * **Barbiturates (A):** These are CNS depressants used as sedatives or anticonvulsants. They have no role in methanol metabolism and would worsen the respiratory depression often seen in severe poisoning. * **Phenytoin (C & D):** This is an antiepileptic drug used for tonic-clonic seizures. While seizures can occur in late-stage methanol poisoning due to cerebral edema, phenytoin is not an antidote and does not address the underlying toxin. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Toxicity:** Methanol → (ADH) → Formaldehyde → (Aldehyde Dehydrogenase) → Formic Acid. * **Classic Presentation:** "Snowstorm vision" (optic papillitis) and high anion gap metabolic acidosis. * **Alternative Antidote:** **Ethanol** (has a higher affinity for ADH than methanol). * **Adjunctive Therapy:** **Folate (Leucovorin)** is administered to enhance the breakdown of formic acid into CO₂ and water. * **Definitive Treatment:** Hemodialysis is indicated if there is visual impairment or severe acidosis.

Question 1

A drug 'X' is more selective for the $\alpha_1$ subtype of GABA-A receptors. It has hypnotic action but absent or little antianxiety, muscle relaxant, and anticonvulsant actions. Which of the following can be 'X'?

Accepted Answer

Zolpidem

Answer

Zopiclone

Answer

Flumazenil

Answer

Melatonin

Question 2

All of the following can result in serotonin syndrome when combined with MAO inhibitors, except?

Accepted Answer

Tyramine containing foods

Answer

Tricyclic antidepressants

Answer

Selective serotonin reuptake inhibitors

Answer

Carbamazepine

Question 3

Nimodipine is used in the management of which condition?

Accepted Answer

Subarachnoid hemorrhage

Answer

Subdural hemorrhage

Answer

Extradural hemorrhage

Answer

Intraventricular hemorrhage

Question 4

Which of the following agents does not bind to GABA receptor chloride channels?

Accepted Answer

Buspirone

Answer

Ethanol

Answer

Alphaxolone

Answer

Zolpidem

Question 5

A person taking tricyclic antidepressants presents with blurred vision and dry mouth. These adverse effects result from the blockade of which receptors?

Accepted Answer

M3 muscarinic receptors

Answer

GABA receptor

Answer

H1 histamine receptors

Answer

5HT2 receptors

Question 6

What drug is given for a metoclopramide-induced dystonic reaction?

Accepted Answer

Promethazine

Answer

Pheniramine

Answer

Chlorpropamide

Answer

Prochlorperazine

Question 7

Which NMDA antagonist is used in the treatment of Alzheimer's disease?

Accepted Answer

Memantine

Answer

Rivastigmine

Answer

Donepezil

Answer

Galantamine

Question 8

Which of the following is the calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA for the treatment of acute migraine attacks?

Accepted Answer

Rimegepant

Answer

Lasmiditan

Answer

Eletriptan

Answer

Erenumab

Question 9

Which drug has proven efficacy in bipolar depression?

Accepted Answer

Lamotrigine

Answer

Carbamazepine

Answer

Valproate

Answer

Tiagabine

Question 10

What is the antidote for methyl alcohol poisoning?

Accepted Answer

Fomepizole

Answer

Barbiturate

Answer

Phenytoin

Answer

Phenytoin

Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?